Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

Autor: J. David Smeijer, Jeroen Koomen, Donald E. Kohan, John J.V. McMurray, George L. Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, James L. Januzzi, Dalane W. Kitzman, Daniel M. Kolansky, Hirofumi Makino, Vlado Perkovic, Sheldon Tobe, Hans-Henrik Parving, Dick de Zeeuw, Hiddo J.L. Heerspink

Publikováno v: JACC Heart Fail
JACC. Heart failure, 10(7), 498-507. ELSEVIER SCI LTD

BACKGROUND: The endothelin receptor antagonist atrasentan reduced the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease (CKD) in the SONAR (Study of Diabetic Nephropathy with Atrasentan) trial, although with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee5cb0019ff35f8d70ca9f0ea04c8b5b
https://doi.org/10.1016/j.jchf.2022.03.004

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation:A Multinational Population-Based Cohort Study

Autor: Wallis C.Y. Lau, Carmen Olga Torre, Kenneth K.C. Man, Henry Morgan Stewart, Sarah Seager, Mui Van Zandt, Christian Reich, Jing Li, Jack Brewster, Gregory Y.H. Lip, Aroon D. Hingorani, Li Wei, Ian C.K. Wong

Publikováno v: Lau, W C Y, Torre, C O, Man, K K C, Stewart, H M, Seager, S, Van Zandt, M, Reich, C, Li, J, Brewster, J, Lip, G Y H, Hingorani, A D, Wei, L & Wong, I C K 2022, ' Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study ', Annals of Internal Medicine, vol. 175, no. 11, pp. 1515-1524 . https://doi.org/10.7326/M22-0511

BACKGROUND: Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC. OBJECTIVE: To do a large-scale comparison

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d793a0a23cf5b2d6eef4a02d1bf54c7e
https://vbn.aau.dk/da/publications/358dedc4-936d-4b8f-8ef3-97b512fadd84

SGLT2 inhibitorsfor treatment of chronic kidney disease without diabetes or heart failure

Autor: Feldt-Rasmussen, Bo, Borg, Rikke, Carstens, Jan, Hansen, Ditte, Hornum, Mads, Lindhardt, Morten, Mose, Frank Holden, Bang Pedersen, Birgitte, Povlsen, Johan, Dyhr Schandorff, Kristine, Strandhave, Charlotte

Publikováno v: Feldt-Rasmussen, B, Borg, R, Carstens, J, Hansen, D, Hornum, M, Lindhardt, M, Mose, F H, Pedersen, B B, Poulsen, J V, Schandorff, K D & Strandhave, C 2022, ' SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt ', Ugeskift for Læger, bind 184, nr. 20, V11210887, s. 1872-1875 . < https://ugeskriftet.dk/videnskab/sglt2-haemning-til-kronisk-nyresygdom-uden-ledsagende-diabetes-eller-hjertesvigt >
Feldt-Rasmussen, B, Borg, R, Carstens, J, Hansen, D, Hornum, M, Lindhardt, M, Mose, F H, Pedersen, B B, Poulsen, J V, Schandorff, K D & Strandhave, C 2022, ' SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt ', Ugeskrift for Laeger, bind 184, nr. 16, V11210887 . < https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-04/v11210887_web.pdf >
Feldt-Rasmussen, B, Borg, R, Carstens, J, Hansen, D, Hornum, M, Lindhardt, M, Mose, F H, Bang Pedersen, B, Povlsen, J, Dyhr Schandorff, K & Strandhave, C 2022, ' SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt ', Ugeskrift for Læger, bind 184, V11210887 . < https://ugeskriftet.dk/videnskab/sglt2-haemning-til-kronisk-nyresygdom-uden-ledsagende-diabetes-eller-hjertesvigt?time=1650374163&utm_campaign=&utm_medium=Ugentlig&utm_source=Newsletter >

This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::471d5bc158004a5a078e32ad2c448668
https://vbn.aau.dk/da/publications/54d666b4-45e7-4f88-ad5e-b53e24ec371a

Hyperuricémie et maladie rénale : prise en charge [Management of hyperuricemia in chronic kidney disease]

Autor: Schwotzer, N., Auberson, M., Livio, F., So, A., Bonny, O.

Publikováno v: Revue medicale suisse, vol. 18, no. 771, pp. 379-384

Hyperuricemia is often encountered as glomerular filtration rate decreased. It is associated with a more rapid decline of the renal function, but causality has not been demonstrated. Recent studies showed that treatment of hyperuricemia did not affec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::e9105eb44f1a3156d7c6b6a053f730d5
https://serval.unil.ch/notice/serval:BIB_2FCE48D8B05C

Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney disease

Autor: Rukshana Shroff, Bruce Green, Sumithra Selvam, Jyoti Sharma, Greta Rait, Mandy Wan, Jyoti Singhal, Nivedita Kamath, Susan Uthup, Arpana Iyengar, Hamsa V. Reddy, Jignesh P. Patel, Sudha Ekambaram

Publikováno v: Wan, M, Green, B, Iyengar, A, Kamath, N, Reddy, H, Sharma, J, Singhal, J, Uthup, S, Ekambaram, S, Selvam, S, Rait, G, Shroff, R & Patel, J 2022, ' Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney disease ', British Journal of Clinical Pharmacology, vol. 88, no. 3, doi.org/10.1111/bcp.15064, pp. 1223-1234 . https://doi.org/10.1111/bcp.15064

AIMS: The prevalence of vitamin D deficiency is high in children with chronic kidney disease (CKD). However, current dosing recommendations are based on limited pharmacokinetic (PK) data. This study aimed to develop a population PK model of colecalci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4160726f144ced16816bd5f9cc488f0e
https://kclpure.kcl.ac.uk/en/publications/cb198942-c275-4a6a-96bc-169031b6b3f2